In a major step toward improving public health and pharmaceutical oversight, Pakistan’s federal cabinet has approved the implementation of a nationwide track-and-trace system designed to eliminate counterfeit medicines from the market.

The digital system will enable authorities to monitor the production, distribution, and sale of medicines through unique identification codes, making it easier to verify authenticity and trace products throughout the supply chain. Officials believe the initiative will significantly reduce the circulation of fake and substandard drugs, which have long posed serious risks to patients across the country.

The move is expected to enhance transparency within the pharmaceutical sector while strengthening regulatory enforcement. By providing real-time tracking capabilities, authorities will be better equipped to identify irregularities, prevent illegal distribution networks, and ensure compliance with quality standards.

Healthcare experts have welcomed the decision, noting that counterfeit medicines not only endanger lives but also undermine trust in the healthcare system. The track-and-trace mechanism is expected to align Pakistan’s pharmaceutical regulations with international best practices and improve overall patient safety.

The cabinet’s approval marks a significant milestone in the government’s broader efforts to modernize healthcare governance, protect consumers, and build a more accountable and efficient pharmaceutical supply chain throughout Pakistan.